Evidence map›Paper›PMID 41663377›Full record

ArticleNature communications2026

Explainable AI-based analysis of human pancreas sections identifies traits of type 2 diabetes.

Lukas Klein, Sebastian Ziegler, Felicia Gerst, Yanni Morgenroth, Karol Gotkowski, Eyke Schöniger, Martin Heni, Nicole Kipke, Daniela Friedland, Annika Seiler and 20 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Lukas Klein *IML Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sebastian Ziegler *Helmholtz Imaging, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Felicia Gerst *Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich (IDM), University of Tübingen, Tübingen, Germany.
Yanni Morgenroth *German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
Karol GotkowskiHelmholtz Imaging, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Eyke SchönigerGerman Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
Martin HeniInternal Medicine I, Endocrinology and Diabetology, University Hospital Ulm, Ulm, Germany.ORCID http://orcid.org/0000-0002-8462-3832
Nicole KipkeGerman Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
Daniela FriedlandGerman Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
Annika SeilerGerman Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
Ellen GeibeltCenter for Molecular and Cellular Bioengineering, Technische Universität Dresden, Light Microscopy Facility, Dresden, Germany.
Hajime YamazakiSection of Clinical Epidemiology, Department of Community Medicine, Kyoto University, Kyoto, Japan.
Hans-Ulrich HäringInstitute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich (IDM), University of Tübingen, Tübingen, Germany.
Silvia WagnerDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Silvio NadalinDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Alfred KönigsrainerDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Andre L MihaljevicDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Daniel HartmannDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Falko FendDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-5496-293X
Daniela AustDepartment of Pathology, University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität Dresden, Dresden, Germany.
Jürgen WeitzGerman Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
Reiner Jumpertz-von SchwartzenbergInstitute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich (IDM), University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-5544-099X
Marius DistlerGerman Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
Klaus Maier-HeinHelmholtz Imaging, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Andreas L BirkenfeldInstitute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich (IDM), University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0003-1407-9023
Susanne UllrichInstitute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich (IDM), University of Tübingen, Tübingen, Germany.
Paul F JägerIML Group, German Cancer Research Center (DKFZ), Heidelberg, Germany. paulfjaeger@icloud.com.
Fabian IsenseeHelmholtz Imaging, German Cancer Research Center (DKFZ), Heidelberg, Germany. f.isensee@dkfz.de.ORCID http://orcid.org/0000-0002-3519-5886
Michele SolimenaGerman Center for Diabetes Research (DZD e.V.), Neuherberg, Germany. michele.solimena@tu-dresden.de.ORCID http://orcid.org/0000-0002-3653-8107
Robert WagnerGerman Center for Diabetes Research (DZD e.V.), Neuherberg, Germany. robert.wagner@uni-duesseldorf.de.ORCID http://orcid.org/0000-0002-6120-0191

Funding

Helmholtz Association Project DIADEM, ZT-1-PF-5 139
6 · The paper itself

Abstract

Type 2 diabetes (T2D) is a chronic disease currently affecting around 500 million people worldwide with often severe health consequences. Yet, histopathological analyses are still inadequate to infer the glycaemic state of a person based on morphological alterations linked to impaired insulin secretion and β-cell failure in T2D. Giga-pixel microscopy can capture subtle morphological changes, but data complexity exceeds human analysis capabilities. In response, we generate a dataset of pancreas whole-slide images from living donors with multiple chromogenic and multiplex immunofluorescence stainings and train deep learning models to predict the T2D status. Using explainable AI, we make the learned relationships interpretable, quantify them as biomarkers, and assess their association with T2D. Remarkably, the highest prediction performance is achieved by simultaneously focusing on islet α- and δ-cells and neuronal axons, alongside subtle pancreatic alterations in T2D donors such as larger adipocyte clusters, altered islet-adipocyte proximity and smaller islets. This data-driven approach provides a foundation for future research into relevant diagnostic and therapeutic targets, refining several hypotheses regarding tissue alterations associated with T2D.

Indexed as

Diabetes Mellitus, Type 2PancreasAdipocytesAxonsBiomarkersData AnalyticsDeep LearningFemaleGlucagon-Secreting CellsHumansInsulin-Secreting CellsIslets of LangerhansSomatostatin-Secreting CellsBiomarkers

Identifiers

PMID41663377
PMCPMC12894717

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.